Medical devices, healthcare technology and the business of care
PMA approval · P140009

BRIO NEUROSTIMULATION SYSTEM

ABBOTT MEDICAL · Decision date Jun 12, 2015

MEDTECHLEDGER EXPLANATIONP140009

What did the FDA approve?

The June 12, 2015 PMA approval for the Brio Neurostimulation System covers two indications. The first is bilateral stimulation of the subthalamic nucleus as adjunctive therapy to reduce some symptoms of advanced levodopa-responsive Parkinson's disease not adequately controlled by medications. The second is unilateral or bilateral stimulation of the ventral intermediate nucleus of the thalamus for suppression of disabling upper extremity tremor in adult essential tremor patients whose tremor is not adequately controlled by medications and constitutes a significant functional disability.

The applicant is Abbott Medical, and the device is categorized as an implanted electrical stimulator for parkinsonian tremor under product code MHY. The FDA statement reports the approved intended uses but does not itself provide clinical data or an independent effectiveness finding. No supplement type or reason is listed, so this record reflects the original PMA approval scope rather than a change to an existing approval.

FDA approval order statement

APPROVAL FOR THE BRIO NEUROSTIMULATION SYSTEM. THIS DEVICE IS INDICATED FOR THE FOLLOWING CONDITIONS:1) BILATERAL STIMULATION OF THE SUBTHALAMIC NUCLEUS (STN) AS AN ADJUNCTIVE THERAPY TO REDUCE SOME OF THE SYMPTOMS OF ADVANCED LEVODOPA-RESPONSIVE PARKINSONS DISEASE THAT ARE NOT ADEQUATELY CONTROLLED BY MEDICATIONS; AND 2) UNILATERAL OR BILATERAL STIMULATION OF THE VENTRAL INTERMEDIATE NUCLEUS (VIM) OF THE THALAMUS FOR THE SUPPRESSION OF DISABLING UPPER EXTREMITY TREMOR IN ADULT ESSENTIALTREMOR PATIENTS WHOSE TREMOR IS NOT ADEQUATELY CONTROLLED BY MEDICATIONS AND WHERE THE TREMOR CONSTITUTES A SIGNIFICANT FUNCTIONAL DISABILITY.
Regulatory pathway
Original PMA
Clinical specialty
Neurology
Decision date
Jun 12, 2015

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P140009
Regulatory pathway
Premarket approval application
Product code
MHY
Decision code
APPR
Decision date
Jun 12, 2015
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Stimulator, electrical, implanted, for parkinsonian tremor.

Product code
MHY
FDA device class
3

The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.

FDA decision timeline

  1. P140009 received

    Application receipt date recorded by FDA.

  2. P140009 · FDA decision

    APPR

  3. P140009/S140 · Related supplement

    Deep Brain Stimulation (DBS) Implantable Pulse Generator (IPG) Charger

  4. P140009/S143 · Related supplement

    Liberta RC Deep Brain Stimulation (DBS) Implantable Pulse Generator

  5. P140009/S141 · Related supplement

    Deep Brain Stimulation (DBS) EPG

  6. P140009/S142 · Related supplement

    Deep Brain Stimulation (DBS) Implantable Pulse Generator (IPG) Charger

  7. P140009/S144 · Related supplement

    Deep Brain Stimulation (DBS) Implantable Pulse Generator (IPG)

Timeline entries are records held by MedtechLedger for P140009. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P140009

Product / regulatory recordCompanyPathwayDecision dateSource
ABBOTT MEDICALPMA supplementSep 11, 2026FDA
Infinity DBS IPGP140009/S139
ABBOTT MEDICALPMA supplementSep 23, 2026FDA
ABBOTT MEDICALPMA supplementOct 27, 2026FDA
ABBOTT MEDICALPMA supplementOct 28, 2026FDA
ABBOTT MEDICALPMA supplementOct 30, 2026FDA
ABBOTT MEDICALPMA supplementOct 30, 2026FDA

Explore the linked device profile

Other records with product code MHY

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Abbott Medical

Headquarters
Not reported
Brand website
abbott.com
FDA applicant address
6901 Prestion Rd., Plano, TX, 75024

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records